Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients will be enrolled and randomized on a 2:1 ratio to either the experimental arm (LiTT + cemiplimab) or the control arm (LiTT + physician/s choice chemotherapy).

NCT Number	NCT07620548
Lead Sponsor	Washington University School of Medicine Collaborators: Regeneron Pharmaceuticals
Conditions	Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Enrollment	99 participants
Start Date	2026-08-31
Primary Completion	2031-02-28 (estimated)
Study Completion	2032-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-02